Therapies and Diagnostics for Uterine Cancer

NEW YORK, Oct. 9, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Therapies and Diagnostics for Uterine Cancer

http://www.reportlinker.com/p01658941/Therapies-and-Diagnostics-for-Uterine-Cancer.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

STUDY GOALS AND OBJECTIVES

This report HLC142A Therapies and Diagnostics for Uterine Cancer provides an overview of the current and potential global market for uterine cancer, treatments, screening and testing technologies. The report provides comprehensive information on uterine cancer, highlighting treatment guidelines. It identifies and analyzes the key trends driving the global uterine cancer therapeutics market. The key objective is to present a comprehensive analysis of current uterine cancer technology and the utilization of the various therapeutic, screening and diagnostic modalities. The report's focus is on uterine disorders, current treatment strategies and drugs, chemotherapy and other treatment modalities and testing and screening methods. Important trends in the field, research, new developments and sales forecasts by treatment and screening categories from 2013 through 2018 are provided. Issues and trends addressed in this report are based on information from industry sources, regulatory and healthcare policies, demographics and other factors that directly affect the uterine cancer market.It also focuses on the treatment usage patterns in the global uterine cancer therapeutics market, competitive landscape, and the emerging players and pipeline products. The report also details opportunities for future players.

REASONS FOR DOING THIS STUDY

This study was conducted to provide detailed information on testing and treatment options for uterine disorders and cancer. There is an increasing need for new and innovative technologies. This industry is experiencing tremendous growth. Many diseases discussed in this report are global issues and a need exists for newer diagnostic and treatment strategies. This study looks at most types of diagnostic and treatment strategies for the clinical management of endometrial disorders and related cancers.This BCC market research report will increase the reader's awareness of current and emerging drugs and technologies for uterine cancers, therapeutics, chemotherapy and surgical therapy.

INTENDED AUDIENCE

This report is a detailed study on the global uterine cancer market, with key statistics and analysis of current drugs and screening and diagnostic technologies, latest trends, market structure, market size, key drug segments and trends in technology. This study contributes to the areas of market growth in uterine cancer prevention and treatment strategies from the point of view of manufacturers, product suppliers, healthcare providers, and consumers of uterine cancer products and services. This study will be largely of interest to the pharmaceutical and biotechnology industries, as well as clinics, hospitals and research institutes. This report may also prove crucial for investment firms in the relative sector. This report discusses tests currently being used for uterine disorders, cancer diagnosis and prognosis, new developments, spending trends and revenue prospects for these technologies. The report provides market data for 2012 to 2018 and also covers commercial prospects, uterine cancer diagnostic tests in use and future growth.

SCOPE OF THE STUDY

The scope of this study is diagnostic test and therapeutic markets for uterine cancers. Screening tests are included as discussion only, as new studies have reflected that Pap smears, CT scans and ultrasound could be used as screening aids for uterine cancer. The exact usage for these tests for uterine cancer is still under research; therefore, sales numbers and revenue forecasts from this segment are not included in the final market summary. The focus of this report is on diagnostic tests and therapeutics for uterine cancer, including surgery and diagnostic methods (e.g., hysteroscopy and endometrial biopsy) that are currently in use. The report also includes discussions on the current technologies, new technologies, incidence, market projections and market share, along with the latest trends and new developments.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, industry news and developments, and paid and free databases. The base year of the report is 2012, with forecast data provided through 2018. Historical, base year and forecast data are provided for each market segment of this report. The report provides a comprehensive review of uterine cancer, incidence and development of the disease, drugs currently being used and diagnostic technologies. The report also reviews technological developments, product innovations/introductions and recent strategic industry activity of major players across various product categories. Growth rates, global incidence and projections are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D and current product growth. Forecasts and projections were based on estimates such as the current trends, potential users, mergers and acquisitions, and market trends.A comprehensive and exhaustive search of the literature on uterine cancer and disorders, products, global incidence and drug development was conducted. These secondary sources included scientific journals and articles, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports and other publications. A patent search and analysis were also conducted. Some informal interviews were also conducted with experts and personnel in this area at biotech and pharmaceutical companies. Other resources included academics, technology and consulting companies.

INFORMATION SOURCES

Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of products such as the pharmaceutical and biotechnical industries and research institutes. Data were gathered from various industry sources. BCC spoke with officials within academia, industry and the medical community, and consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

ABOUT THE AUTHOR

Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification, including Investigational New Drug (IND) enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.

REPORT HIGHLIGHTS

This report provides:• An overview of the global market for diagnostics and therapies for uterine cancer• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018• A breakdown of the markets by diagnostics and screening, surgery, radiation therapy, and drug therapy• Discussion of uterine cancer biology• Delineation of drugs approved and in the pipeline to treat the disease, including chemotherapeutic and immunotherapeutic• Evaluation of the patent landscape• Comprehensive profiles of key companies.

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2REASONS FOR DOING THIS STUDY 2INTENDED AUDIENCE 2SCOPE OF THE STUDY 3METHODOLOGY 3INFORMATION SOURCES 3ABOUT THE AUTHOR 4RELATED BCC REPORTS 4BCC ONLINE SERVICES 4DISCLAIMER 4

CHAPTER 2 SUMMARY 7

SUMMARY TABLE UTERINE/ENDOMETRIAL CANCER: TREATMENT ANDDIAGNOSTICS, GLOBAL MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 8SUMMARY FIGURE UTERINE/ENDOMETRIAL CANCER: TREATMENT ANDDIAGNOSTICS, GLOBAL MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 9

CHAPTER 3 OVERVIEW 11

GYNECOLOGIC CANCERS 11CANCER 11TABLE 1 LIFESTYLE CHANGES THAT HELP REDUCE THE PREVALENCE OF CANCER 12ENDOMETRIAL/UTERINE CANCER 13TABLE 2 KEY CLINICAL FEATURES OF UTERINE CANCER 13TABLE 3 HISTOLOGY OF ADENOCARCINOMA 15CAUSES/RISK FACTORS 15Hormone Factors 16TABLE 4 RISK FACTORS 16Estrogen 17Estrogen Therapy 17Oral Contraceptives 17Total Number of Menstrual Cycles 17Pregnancy 17Obesity 18Treatment with Tamoxifen 18Ovarian Tumors 18Polycystic Ovarian Syndrome 18Use of an Intrauterine Device 19Age 19Diet and Exercise 19Diabetes 19Genetics 19TABLE 5 GENES: CAUSE OF HEREDITARY NONPOLYPOSIS COLON CANCER (HNPCC) 20Breast Cancer 20Prior Pelvic Radiation Therapy 20Endometrial Hyperplasia 20CLASSIFICATION 20Carcinoma 20TABLE 6 ENDOMETRIAL CARCINOMAS CLASSIFIED INTO TWO PATHOGENETICGROUPS 21Sarcoma 21TABLE 7 CARCINOMA OF THE ENDOMETRIUM 22ENDOMETRIAL CANCER SYMPTOMS 22TABLE 8 SIGNS AND SYMPTOMS 23DIAGNOSIS 23Clinical Evaluation 23TABLE 9 UTERINE CANCER: DIAGNOSIS 24Tests 24TABLE 10 DIAGNOSTIC TESTS 24TABLE 11 STAGES OF ENDOMETRIAL CANCER 25Pathology 25TREATMENT 26TABLE 12 TREATMENT DEPENDS UPON THE STAGE 26Uterine Cancer Treatment is Based on Several Important Factors 27PROGNOSIS 28Survival Rates 28TABLE 13 FIVE-YEAR SURVIVAL RATES (%) 29TABLE 14 UTERINE CARCINOSARCOMA: FIVE-YEAR SURVIVAL RATES BY STAGE (%) 29EPIDEMIOLOGY 30COMPLICATIONS 30PREVENTION 30

CHAPTER 4 UTERINE CANCER: BIOLOGY 32

UTERUS AND ENDOMETRIUM 32UTERINE CANCER 32TABLE 15 TYPES OF UTERINE CANCERS 33CLINICAL PRESENTATION 33ESTROGEN'S ROLE 34TYPES OF ENDOMETRIAL CANCER 34Carcinoma 34Type I Endometrial Carcinoma 34Type II Endometrial Carcinoma 35Endometrioid Cancer: Grade 35TABLE 16 GRADING 35Uterine Sarcomas 36TUMOR MARKERS 36Types of Gynecologic Tumor Markers 37TABLE 17 IMPORTANT GYNECOLOGIC TUMOR MARKERS 37TABLE 18 POTENTIAL GYNECOLOGIC TUMOR MARKERS 37Clinical Usefulness of Tumor Markers 38Expression of L1CAM Protein Predicts Recurrence of EndometrialCancer 38GENOMIC CLASSIFICATION OF ENDOMETRIAL CANCERS 39Treatment Planning Based on Genomic Information: Advantages 39Study Details 40Summary/Key Facts from the Study 41TABLE 19 UTERINE CANCER GENOMIC SUBTYPES: KEY CHARACTERISTICS 42CONCLUSIONS 42

CHAPTER 5 UTERINE CANCER DIAGNOSIS AND SCREENING 45

SCREENING FOR ENDOMETRIAL CANCER 45CAN ENDOMETRIAL CANCER BE FOUND EARLY? 45Early Detection Tests 46STAGING 46TABLE 20 STAGING OF UTERINE CANCER 46SCREENING PROCEDURES 46Low Endometrial Cancer Risk 46High Endometrial Cancer Risk 47Current Screening Methods 47Endometrial Cancer Diagnosis 47Clinical Evaluation 48DIAGNOSTIC TESTS FOR ENDOMETRIAL CANCER 48TABLE 21 UTERINE CANCER SCREENING TESTS OR PROCEDURES 48Dilatation and Curettage (D&C) 48Pap Test 49Transvaginal Ultrasound 49Hydroultrasound 49Endometrial Biopsy 50Hysteroscopy 50Other Lab Tests 50Tumor Markers 50Other Tests 51Routine Blood Tests 51New Test: GynEC-Dx 51TABLE 22 GYNECDX KEY FEATURES 52

CHAPTER 6 UTERINE CANCER TREATMENT STRATEGIES 54

ENDOMETRIAL CANCER RESEARCH 54HISTOPATHOLOGICAL CHARACTERISTICS 55MOLECULAR PATHOLOGY OF ENDOMETRIAL CANCER 55TUMOR MARKERS 55TREATMENT STRATEGIES 56SURGERY 56Surgical Treatment in Stage I Endometrial Cancer 57Surgical Treatment in Stage II Endometrial Cancer 57Surgical Treatment in Stage III-IV Endometrial Cancer 57Hysterectomy 57TABLE 23 CONDITIONS UNDER WHICH HYSTERECTOMY IS PERFORMED 58Other Options to Hysterectomy 58Nerve Block 58Medication Therapy 59Myomectomy 59Ablation 59Balloon Therapy 59Hysterectomy Surgical Procedures 59TABLE 24 TYPES OF HYSTERECTOMY PROCEDURES 60Radiation Therapy 60Radiation Therapy for Endometrial Cancer 61TABLE 25 TWO TYPES OF RADIATION THERAPY TO TREAT ENDOMETRIAL CANCER 61TABLE 26 RADIATION THERAPY: SIDE EFFECTS 61Risks 62TABLE 27 SIDE EFFECTS OF RADIATION 62Chemotherapy 62Combined Radiotherapy-Chemotherapy 63Locoregional Recurrence 63Advanced Disease 63Treatment of Metastatic Disease and Relapse 64Papillary Serous Carcinoma and Clear Cell Carcinoma 64Hormone Therapy 65NEW THERAPEUTICS IN DEVELOPMENT 66TABLE 28 DRUGS CURRENTLY IN USE TO TREAT UTERINE CANCERS 66TABLE 29 COMBINATION PRODUCTS USED FOR TREATING UTERINE CANCER 68TABLE 30 DRUGS IN THE PIPELINE 70CONCLUSIONS 71

CHAPTER 7 UTERINE CANCER INCIDENCE 73

TABLE 31 KEY FACTS: CANCER 73TABLE 32 PREVENTION STRATEGIES 75EARLY DETECTION 75SCREENING 75TREATMENT 75UTERINE CANCER GLOBAL INCIDENCE 76TABLE 33 GLOBAL INCIDENCE OF UTERINE CANCER, 2008–2018 76TABLE 34 GLOBAL CORPUS UTERINE CANCER (C54) 2008 ESTIMATES: WORLDAGE-STANDARDIZED INCIDENCE RATES PER 100,000 WOMEN BY REGION 77TABLE 35 UNITED KINGDOM: AGE-STANDARDIZED RATES AND NUMBER OFUTERINE CANCER DIAGNOSES PER 100,000 WOMEN, 2007 AND 2030 78NORTHERN AMERICA 79United States 79TABLE 36 UNITED STATES: UTERINE CANCER INCIDENCE AND MORTALITY,2011–2013 79TABLE 37 KEY FINDINGS 80INCIDENCE AND MORTALITY 81Surveillance, Epidemiology and End Results (SEER) Incidence 81TABLE 38 INCIDENCE RATES BY RACE 81U.S. Mortality 81TABLE 39 DEATH RATES BY RACE 82SURVIVAL AND STAGE 82TABLE 40 STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL OF ALL RACESBY STAGE AT DIAGNOSIS, 2003–2009 (%) 82LIFETIME RISK 83PREVALENCE 83INTERVENTIONS ASSOCIATED WITH DECREASED RISK 83Oral Contraceptives 83Physical Activity 84Increasing Parity and Lactation 84INTERVENTIONS ASSOCIATED WITH INCREASED RISK 84Endogenous Estrogen 84Exogenous Estrogen: Postmenopausal Hormone Therapy (HT) 84Combination Estrogen-Progestin Replacement Therapy 85Selective Estrogen Receptor Modulators (SERMs): Tamoxifen andRaloxifene 85Obesity 86Increasing Age 86Genetic Predisposition 86INTERVENTIONS OF UNPROVEN OR DISPROVEN EFFECT ON RISK 86Weight Loss 86Fruits, Vegetables and Vitamins 87EUROPE 87Trends in Postmenopausal Women 88Trends in Premenopausal Women 89United Kingdom 90TABLE 41 UNITED KINGDOM UTERINE CANCER INCIDENCE, NUMBER OF NEWCASES, CRUDE AND EUROPEAN AGE-STANDARDIZED (AS) INCIDENCE RATES PER100,000 POPULATION, 200891TABLE 42 UNITED KINGDOM: GYNECOLOGICAL CANCERS, NUMBER OF NEW CASESAND EUROPEAN AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000POPULATION, 200891INDIA 92

CHAPTER 8 GLOBAL MARKET FOR UTERINE CANCER TREATMENTS AND DIAGNOSTICS 94

CANCER: GLOBAL COSTS 94

CANCER IN THE UNITED STATES 95TABLE 43 UNITED STATES: NUMBER OF CANCER SURVIVORS, 2010 AND 2020(NUMBER%) 95TABLE 44 UNITED STATES: PROJECTED COST OF UTERINE CANCER CARE, 2010AND 2020 ($ MILLIONS/%) 96TABLE 45 UNITED STATES: NUMBER OF UTERINE CANCER SURVIVORS, 2010 AND2020 (NUMBER/%) 97TABLE 46 UNITED STATES: NUMBER OF SURVIVORS OF GYNECOLOGICAL CANCERSBY TYPE, 2010 AND 2020 (NUMBER/%) 97CURRENT ENDOMETRIAL CANCER SCREENING AND DIAGNOSIS 98SCREENING 98TABLE 47 CURRENT TESTS FOR UTERINE CANCER 98DIAGNOSIS 98GLOBAL MARKET FOR UTERINE CANCER DIAGNOSTIC TESTS 99TABLE 48 GLOBAL UTERINE CANCER DIAGNOSTIC TESTS: MARKET AND FORECAST,THROUGH 2018 ($ MILLIONS) 99FIGURE 1 GLOBAL UTERINE CANCER DIAGNOSTIC TESTS: MARKET AND FORECAST,2012-2018 ($ MILLIONS) 99GLOBAL MARKET FOR ENDOMETRIAL SAMPLING 100TABLE 49 GLOBAL MARKET FOR ENDOMETRIAL BIOPSY FOR UTERINE CANCER:SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 101FIGURE 2 GLOBAL MARKET FOR ENDOMETRIAL BIOPSY FOR UTERINE CANCER:SALES AND FORECAST 2012-2018 ($ MILLIONS) 101Dilation and Curettage 101GLOBAL MARKET FOR HYSTEROSCOPIES 102TABLE 50 GLOBAL MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER:SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 102FIGURE 3 GLOBAL MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER:SALES AND FORECAST, 2012-2018 ($ MILLIONS) 102U.S. Market for Hysteroscopies 103TABLE 51 U.S. MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER: SALESAND FORECAST, THROUGH 2018 ($ MILLIONS) 103FIGURE 4 U.S. MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER: SALESAND FORECAST, 2012-2018 ($ MILLIONS) 103Testing of Endometrial Tissue 104GLOBAL PAP SMEAR TEST MARKET 104TABLE 52 CURRENT CERVICAL CANCER SCREENING 105TABLE 53 GLOBAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TEST, MARKET ANDFORECAST, THROUGH 2018 ($ MILLIONS) 106FIGURE 5 GLOBAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TEST MARKET ANDFORECAST, 2012-2018 ($ MILLIONS) 106U.S. PAP SMEAR MARKET 106TABLE 54 NUMBER OF PAP SMEAR TESTS PERFORMED IN THE U.S. AND EUROPE,2012 AND 2013 ($ MILLIONS) 107TABLE 55 U.S.: PERCENTAGE OF PAP SMEAR TESTS PERFORMED, 2008 AND 2010 107TABLE 56 U.S.: PERCENTAGE OF WOMEN WHO RECEIVE PAP SMEAR TESTS,AGE-STRATIFIED, 2008 AND 2010 108TABLE 57 PAP TESTS ORDERED OR PROVIDED IN THE U.S., 2010 108TABLE 58 PAP TESTS ORDERED OR PROVIDED AT OUTPATIENT VISITS IN THE U.S.,2010 109GLOBAL COST OF PAP SMEARS 109LATEST TECHNOLOGY 109GLOBAL MARKET FOR TRANSVAGINAL ULTRASOUND 110TABLE 59 GLOBAL MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES ANDFORECAST, THROUGH 2018 ($ MILLIONS) 112FIGURE 6 GLOBAL MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES ANDFORECAST, 2012-2018 ($ MILLIONS) 112U.S. MARKET FOR TRANSVAGINAL ULTRASOUNDS 113TABLE 60 U.S. MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES ANDFORECAST, THROUGH 2018 ($ MILLIONS) 113FIGURE 7 U.S. MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES ANDFORECAST, 2012-2018 ($ MILLIONS) 113OTHER TESTS FOR ENDOMETRIAL CANCER 113Cystoscopy and Proctoscopy 113OTHER IMAGING TESTS 114TABLE 61 IMAGING TESTS 114Magnetic Resonance Imaging (MRI) 114Positron Emission Tomography (PET) 115Chest X-ray 115Blood Tests 115Complete Blood Count 115GLOBAL MARKET FOR COMPUTED TOMOGRAPHY (CT) 115TABLE 62 GLOBAL COMPUTED TOMOGRAPHY IMAGING MARKET FOR UTERINECANCER: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 116FIGURE 8 GLOBAL COMPUTED TOMOGRAPHY IMAGING MARKET FOR UTERINECANCER: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 116U.S. MARKET FOR COMPUTED TOMOGRAPHY (CT) 116TABLE 63 U.S. COMPUTED TOMOGRAPHY IMAGING MARKET FOR CANCER: SALESAND FORECAST, THROUGH 2018 ($ MILLIONS) 117FIGURE 9 U.S. COMPUTED TOMOGRAPHY IMAGING MARKET FOR CANCER: SALESAND FORECAST, 2012-2018 ($ MILLIONS) 117GLOBAL CA-125 TEST MARKET 117TABLE 64 ELEVATED CA-125 LEVEL 118TABLE 65 GLOBAL DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES ANDFORECAST, THROUGH 2018 ($ MILLIONS) 119FIGURE 10 GLOBAL DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES ANDFORECAST, 2012-2018 ($ MILLIONS) 119U.S. CA-125 TEST MARKET 119TABLE 66 U.S. DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST,THROUGH 2018 ($ MILLIONS) 120FIGURE 11 U.S. DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST,2012-2018 ($ MILLIONS) 120GENETIC TESTING 120TABLE 67 GENETIC COUNSELING MAY BE RECOMMENDED 121MOLECULAR DIAGNOSTICS 121PAPGENE TEST 121CONCLUSIONS 122

CHAPTER 9 TREATMENT MARKET 125

ENDOMETRIAL CANCER: CURRENT PRACTICES 125TABLE 68 SEVERAL RECOGNIZED PATHOLOGIC AND CLINICAL FACTORS FOR RISKOF RELAPSE AFTER SURGERY 125GLOBAL MARKET FOR ENDOMETRIAL CANCER TREATMENTS 126TABLE 69 GLOBAL ENDOMETRIAL CANCER MARKET: SALES AND FORECAST BYAPPLICATION TYPE, THROUGH 2018 ($ MILLIONS) 126FIGURE 12 GLOBAL ENDOMETRIAL CANCER MARKET: SALES AND FORECAST BYAPPLICATION TYPE, 2012-2018 ($ MILLIONS) 126GLOBAL MARKET FOR RADIATION THERAPY TO TREAT UTERINE CANCER 127Vaginal Brachytherapy 127TABLE 70 TYPES OF VAGINAL BRACHYTHERAPY 127External Beam Radiation Therapy 128TABLE 71 SIDE EFFECTS OF RADIATION THERAPY 128TABLE 72 GLOBAL MARKET FOR RADIATION USED TO TREAT UTERINE CANCER:SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 129FIGURE 13 GLOBAL MARKET FOR RADIATION USED TO TREAT UTERINE CANCER:SALES AND FORECAST, 2012-2018 ($ MILLIONS) 129U.S. Market for Radiation Therapy to Treat Uterine Cancer 130TABLE 73 U.S. MARKET FOR RADIATION USED TO TREAT UTERINE CANCER: SALESAND FORECAST, THROUGH 2018c ($ MILLIONS) 131FIGURE 14 U.S. MARKET FOR RADIATION USED TO TREAT UTERINE CANCERMARKET: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 131CHEMOTHERAPY 132TABLE 74 COMMON SIDE EFFECTS OF CHEMOTHERAPY 132GLOBAL UTERINE DRUG TREATMENT MARKET 132TABLE 75 GLOBAL MARKET FOR DRUGS TO TREAT UTERINE CANCER, THROUGH2018 ($ MILLIONS) 133GLOBAL MARKET FOR CYTOTOXIC THERAPIES 133TABLE 76 CYTOTOXIC THERAPIES: INDICATIONS 134TABLE 77 GLOBAL CYTOTOXIC MARKET, 2010 AND 2017 ($ MILLIONS) 134FIGURE 15 GLOBAL CYTOTOXIC THERAPY MARKET, 2010 AND 2017 ($ MILLIONS) 134U.S. Market for Cytotoxic Therapies 135TABLE 78 U.S. CYTOTOXIC THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 135FIGURE 16 U.S. CYTOTOXIC THERAPY MARKET, 2012-2018 ($ MILLIONS) 135European Market for Cytotoxic Therapies 135TABLE 79 EUROPEAN CYTOTOXIC THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 136FIGURE 17 EUROPEAN CYTOTOXIC THERAPY MARKET, 2012-2018 ($ MILLIONS) 136Japanese Market for Cytotoxic Therapies 136TABLE 80 JAPANESE CYTOTOXIC THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 137FIGURE 18 JAPANESE CYTOTOXIC THERAPY MARKET, 2012-2018 ($ MILLIONS) 137Drawbacks of Chemotherapy 137Drugs Used in Chemotherapy 138TABLE 81 DRUGS USED TO TREAT UTERINE CANCER 138Paclitaxel 138TABLE 82 UTERINE CANCER: CISPLATIN SALES, 2010 ($ MILLIONS) 139Carboplatin 139TABLE 83 UTERINE CANCER: CARBOPLATIN SALES, 2010-2012 ($ MILLIONS) 139Cisplatin 139Hycamtin 140TABLE 84 UTERINE CANCER: HYCAMTIN SALES, 2010-2012 ($ MILLIONS) 140Avastin 140TABLE 85 UTERINE CANCER: AVASTIN SALES AND FORECAST, THROUGH 2018 ($MILLIONS) 141Cisplatin + Paclitaxel 141Depo-Provera 141Megestrol + Tamoxifen 142AEZS-108 142Ixabepilone 142Ridaforolimus (Deforolimus, AP23573) 143SAR245408 (XL147) 145HORMONE THERAPY FOR ENDOMETRIAL CANCER 145Progestins 145Tamoxifen 145Gonadotropin-releasing Hormone Agonists 145Aromatase Inhibitors 146UTERINE CANCER MARKET AND CHINA 146UTERINE CANCER MARKET AND INDIA 146Hysterectomies in India 146TABLE 86 COSTS OF A HYSTERECTOMY IN INDIA COMPARED WITH THE COSTS INTHE U.S., 2012 ($) 147ENDOMETRIAL CANCER IN YOUNG WOMEN 147CANCER IN THE OBESE PATIENT OR MEDICALLY INOPERABLE WOMAN 147INCOMPLETELY STAGED PATIENTS 147TREATING MENOPAUSAL SYMPTOMS 148SURGICAL TREATMENTS OF ENDOMETRIAL CANCER 148Incidence of Hysterectomy 148TABLE 87 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLYWORLDWIDE 148TABLE 88 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY INNORTH AMERICA 149TABLE 89 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY INCENTRAL AMERICA 149TABLE 90 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY INSOUTH AMERICA, 150TABLE 91 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY INEUROPE 150TABLE 92 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY INASIA 151TABLE 93 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY INTHE MIDDLE EAST 152TABLE 94 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY INNORTHERN AFRICA 152TABLE 95 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY INTHE OCEANIA REGION 153Robotic Surgery 154TABLE 96 HYSTERECTOMY FACTS 155da Vinci System 155Incidence of Hysterectomy in the United Kingdom 156Global Incidence of Hysterectomy 156TABLE 97 GLOBAL ESTIMATES OF THE NUMBER OF HYSTERECTOMIES PERFORMEDANNUALLY BY TYPE 156UTERINE CANCER SURGERY MARKET 157Revenues from Hysterectomies 157TABLE 98 ESTIMATED GLOBAL REVENUES FROM HYSTERECTOMY PROCEDURES BYTYPE, 2013 ($ MILLIONS) 157TABLE 99 UNITED STATES AND CANADA: NUMBER OF HYSTERECTOMYPROCEDURES PERFORMED ANNUALLY BY TYPE, 2013 ESTIMATES 157TABLE 100 UNITED STATES AND CANADA: HYSTERECTOMY PROCEDURES: SALESAND FORECAST, 2013 ($ MILLIONS) 158TABLE 101 KEY EUROPEAN COUNTRIES: HYSTERECTOMY PROCEDURES: SALESAND FORECAST, 2013 ($ MILLIONS) 158TABLE 102 KEY ASIAN COUNTRIES: HYSTERECTOMY PROCEDURES: SALES ANDFORECAST 2013 ($ MILLIONS) 159Revenues from Hysterectomies by Type 159TABLE 103 GLOBAL MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER:SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 159FIGURE 19 GLOBAL MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER:SALES AND FORECAST, 2012-2018 ($ MILLIONS) 159U.S. Revenues from Hysterectomies by Type 160TABLE 104 U.S. MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER:SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 160FIGURE 20 U.S. MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER:SALES AND FORECAST, 2011-2018 160Hysterectomies in India 161ALTERNATE THERAPIES 161Uterine Balloon Therapy 161Myomectomy 161Transcervical Resection of Endometrium (TCRE) 162Hysteroscopic Polypectomy 162Mirena (Hormone Loaded Intrauterine Device) 162Agonadotropin-Releasing Hormone Agonist (GnRH Agonist) 162Uterine Artery Embolization (UAE) 163MRI Guided Focused Ultrasound 163CT Scan 163CONCLUSION 163

CHAPTER 10 PATENT LANDSCAPE 166

GLOBAL IMPACT OF PATENT EXPIRIES 166PATENT LANDSCAPE 166HYCAMTIN (TOPOTECAN HYDROCHLORIDE) 167TABLE 105 PATENT EXPIRIES ON CANCER CHEMOTHERAPY DRUGS 167CISPLATIN 168AVASTIN 168

CHAPTER 11 SELECTED COMPANY PROFILES 170

ABBOTT LABORATORIES 170AETERNA ZENTARIS INC. 170ASTRAZENECA 170BECTON, DICKINSON AND CO. 171BRISTOL-MYERS SQUIBB 171EXELIXIS 171FEMASYS 172GLAXOSMITHKLINE 172INTUITIVE SURGICAL 172JOHNSON & JOHNSON 172MERCK 173ORYZON GENOMICS 173PFIZER 174QIAGEN 174QUEST DIAGNOSTICS 175RJ MADRID 175ROCHE DIAGNOSTICS 176SANOFI 176SIEMENS AG 176TAJ PHARMACEUTICALS 176TEVA PHARMACEUTICAL INDUSTRIES 177VARIAN MEDICAL SYSTEMS 177

CHAPTER 12 BIBLIOGRAPHY 179

LIST OF TABLES

SUMMARY TABLE UTERINE/ENDOMETRIAL CANCER: TREATMENT AND DIAGNOSTICS,

GLOBAL MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 8

TABLE 1 LIFESTYLE CHANGES THAT HELP REDUCE THE PREVALENCE OF CANCER 12

TABLE 2 KEY CLINICAL FEATURES OF UTERINE CANCER 13

TABLE 3 HISTOLOGY OF ADENOCARCINOMA 15

TABLE 4 RISK FACTORS 16

TABLE 5 GENES: CAUSE OF HEREDITARY NONPOLYPOSIS COLON CANCER (HNPCC) 20

TABLE 6 ENDOMETRIAL CARCINOMAS CLASSIFIED INTO TWO PATHOGENETIC

GROUPS 21

TABLE 7 CARCINOMA OF THE ENDOMETRIUM 22

TABLE 8 SIGNS AND SYMPTOMS 23

TABLE 9 UTERINE CANCER: DIAGNOSIS 24

TABLE 10 DIAGNOSTIC TESTS 24

TABLE 11 STAGES OF ENDOMETRIAL CANCER 25

TABLE 12 TREATMENT DEPENDS UPON THE STAGE 26

TABLE 13 FIVE-YEAR SURVIVAL RATES (%) 29

TABLE 14 UTERINE CARCINOSARCOMA: FIVE-YEAR SURVIVAL RATES BY STAGE (%) 29

TABLE 15 TYPES OF UTERINE CANCERS 33

TABLE 16 GRADING 35

TABLE 17 IMPORTANT GYNECOLOGIC TUMOR MARKERS 37

TABLE 18 POTENTIAL GYNECOLOGIC TUMOR MARKERS 37

TABLE 19 UTERINE CANCER GENOMIC SUBTYPES: KEY CHARACTERISTICS 42

TABLE 20 STAGING OF UTERINE CANCER 46

TABLE 21 UTERINE CANCER SCREENING TESTS OR PROCEDURES 48

TABLE 22 GYNECDX KEY FEATURES 52

TABLE 23 CONDITIONS UNDER WHICH HYSTERECTOMY IS PERFORMED 58

TABLE 24 TYPES OF HYSTERECTOMY PROCEDURES 60

TABLE 25 TWO TYPES OF RADIATION THERAPY TO TREAT ENDOMETRIAL CANCER 61

TABLE 26 RADIATION THERAPY: SIDE EFFECTS 61

TABLE 27 SIDE EFFECTS OF RADIATION 62

TABLE 28 DRUGS CURRENTLY IN USE TO TREAT UTERINE CANCERS 66

TABLE 29 COMBINATION PRODUCTS USED FOR TREATING UTERINE CANCER 68

TABLE 30 DRUGS IN THE PIPELINE 70

TABLE 31 KEY FACTS: CANCER 73

TABLE 32 PREVENTION STRATEGIES 75

TABLE 33 GLOBAL INCIDENCE OF UTERINE CANCER, 2008–2018 76

TABLE 34 GLOBAL CORPUS UTERINE CANCER (C54) 2008 ESTIMATES: WORLD

AGE-STANDARDIZED INCIDENCE RATES PER 100,000 WOMEN BY REGION 77

TABLE 35 UNITED KINGDOM: AGE-STANDARDIZED RATES AND NUMBER OF UTERINE

CANCER DIAGNOSES PER 100,000 WOMEN, 2007 AND 2030 78

TABLE 36 UNITED STATES: UTERINE CANCER INCIDENCE AND MORTALITY,

2011–2013 79

TABLE 37 KEY FINDINGS 80

TABLE 38 INCIDENCE RATES BY RACE 81

TABLE 39 DEATH RATES BY RACE 82

TABLE 40 STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL OF ALL RACES

BY STAGE AT DIAGNOSIS, 2003–2009 (%) 82

TABLE 41 UNITED KINGDOM UTERINE CANCER INCIDENCE, NUMBER OF NEW CASES,

CRUDE AND EUROPEAN AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000

POPULATION, 2008

91

TABLE 42 UNITED KINGDOM: GYNECOLOGICAL CANCERS, NUMBER OF NEW CASES

AND EUROPEAN AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000

POPULATION, 2008

91

TABLE 43 UNITED STATES: NUMBER OF CANCER SURVIVORS, 2010 AND 2020

(NUMBER%) 95

TABLE 44 UNITED STATES: PROJECTED COST OF UTERINE CANCER CARE, 2010 AND

2020 ($ MILLIONS/%) 96

TABLE 45 UNITED STATES: NUMBER OF UTERINE CANCER SURVIVORS, 2010 AND

2020 (NUMBER/%) 97

TABLE 46 UNITED STATES: NUMBER OF SURVIVORS OF GYNECOLOGICAL CANCERS

BY TYPE, 2010 AND 2020 (NUMBER/%) 97

TABLE 47 CURRENT TESTS FOR UTERINE CANCER 98

TABLE 48 GLOBAL UTERINE CANCER DIAGNOSTIC TESTS: MARKET AND FORECAST,

THROUGH 2018 ($ MILLIONS) 99

TABLE 49 GLOBAL MARKET FOR ENDOMETRIAL BIOPSY FOR UTERINE CANCER:

SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 101

TABLE 50 GLOBAL MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER:

SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 102

TABLE 51 U.S. MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER: SALES

AND FORECAST, THROUGH 2018 ($ MILLIONS) 103

TABLE 52 CURRENT CERVICAL CANCER SCREENING 105

TABLE 53 GLOBAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TEST, MARKET AND

FORECAST, THROUGH 2018 ($ MILLIONS) 106

TABLE 54 NUMBER OF PAP SMEAR TESTS PERFORMED IN THE U.S. AND EUROPE,

2012 AND 2013 ($ MILLIONS) 107

TABLE 55 U.S.: PERCENTAGE OF PAP SMEAR TESTS PERFORMED, 2008 AND 2010 107

TABLE 56 U.S.: PERCENTAGE OF WOMEN WHO RECEIVE PAP SMEAR TESTS,

AGE-STRATIFIED, 2008 AND 2010 108

TABLE 57 PAP TESTS ORDERED OR PROVIDED IN THE U.S., 2010 108

TABLE 58 PAP TESTS ORDERED OR PROVIDED AT OUTPATIENT VISITS IN THE U.S.,

2010 109

TABLE 59 GLOBAL MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND

FORECAST, THROUGH 2018 ($ MILLIONS) 112

TABLE 60 U.S. MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND FORECAST,

THROUGH 2018 ($ MILLIONS) 113

TABLE 61 IMAGING TESTS 114

TABLE 62 GLOBAL COMPUTED TOMOGRAPHY IMAGING MARKET FOR UTERINE

CANCER: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 116

TABLE 63 U.S. COMPUTED TOMOGRAPHY IMAGING MARKET FOR CANCER: SALES

AND FORECAST, THROUGH 2018 ($ MILLIONS) 117

TABLE 64 ELEVATED CA-125 LEVEL 118

TABLE 65 GLOBAL DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST,

THROUGH 2018 ($ MILLIONS) 119

TABLE 66 U.S. DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST,

THROUGH 2018 ($ MILLIONS) 120

TABLE 67 GENETIC COUNSELING MAY BE RECOMMENDED 121

TABLE 68 SEVERAL RECOGNIZED PATHOLOGIC AND CLINICAL FACTORS FOR RISK

OF RELAPSE AFTER SURGERY 125

TABLE 69 GLOBAL ENDOMETRIAL CANCER MARKET: SALES AND FORECAST BY

APPLICATION TYPE, THROUGH 2018 ($ MILLIONS) 126

TABLE 70 TYPES OF VAGINAL BRACHYTHERAPY 127

TABLE 71 SIDE EFFECTS OF RADIATION THERAPY 128

TABLE 72 GLOBAL MARKET FOR RADIATION USED TO TREAT UTERINE CANCER:

SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 129

TABLE 73 U.S. MARKET FOR RADIATION USED TO TREAT UTERINE CANCER: SALES

AND FORECAST, THROUGH 2018C ($ MILLIONS) 131

TABLE 74 COMMON SIDE EFFECTS OF CHEMOTHERAPY 132

TABLE 75 GLOBAL MARKET FOR DRUGS TO TREAT UTERINE CANCER, THROUGH

2018 ($ MILLIONS) 133

TABLE 76 CYTOTOXIC THERAPIES: INDICATIONS 134

TABLE 77 GLOBAL CYTOTOXIC MARKET, 2010 AND 2017 ($ MILLIONS) 134

TABLE 78 U.S. CYTOTOXIC THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 135

TABLE 79 EUROPEAN CYTOTOXIC THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 136

TABLE 80 JAPANESE CYTOTOXIC THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 137

TABLE 81 DRUGS USED TO TREAT UTERINE CANCER 138

TABLE 82 UTERINE CANCER: CISPLATIN SALES, 2010 ($ MILLIONS) 139

TABLE 83 UTERINE CANCER: CARBOPLATIN SALES, 2010-2012 ($ MILLIONS) 139

TABLE 84 UTERINE CANCER: HYCAMTIN SALES, 2010-2012 ($ MILLIONS) 140

TABLE 85 UTERINE CANCER: AVASTIN SALES AND FORECAST, THROUGH 2018 ($

MILLIONS) 141

TABLE 86 COSTS OF A HYSTERECTOMY IN INDIA COMPARED WITH THE COSTS IN

THE U.S., 2012 ($) 147

TABLE 87 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY

WORLDWIDE 148

TABLE 88 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN

NORTH AMERICA 149

TABLE 89 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN

CENTRAL AMERICA 149

TABLE 90 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN

SOUTH AMERICA, 150

TABLE 91 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN

EUROPE 150

TABLE 92 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN

ASIA 151

TABLE 93 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN THE

MIDDLE EAST 152

TABLE 94 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN

NORTHERN AFRICA 152

TABLE 95 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN THE

OCEANIA REGION 153

TABLE 96 HYSTERECTOMY FACTS 155

TABLE 97 GLOBAL ESTIMATES OF THE NUMBER OF HYSTERECTOMIES PERFORMED

ANNUALLY BY TYPE 156

TABLE 98 ESTIMATED GLOBAL REVENUES FROM HYSTERECTOMY PROCEDURES BY

TYPE, 2013 ($ MILLIONS) 157

TABLE 99 UNITED STATES AND CANADA: NUMBER OF HYSTERECTOMY PROCEDURES

PERFORMED ANNUALLY BY TYPE, 2013 ESTIMATES 157

TABLE 100 UNITED STATES AND CANADA: HYSTERECTOMY PROCEDURES: SALES

AND FORECAST, 2013 ($ MILLIONS) 158

TABLE 101 KEY EUROPEAN COUNTRIES: HYSTERECTOMY PROCEDURES: SALES AND

FORECAST, 2013 ($ MILLIONS) 158

TABLE 102 KEY ASIAN COUNTRIES: HYSTERECTOMY PROCEDURES: SALES AND

FORECAST 2013 ($ MILLIONS) 159

TABLE 103 GLOBAL MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER:

SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 159

TABLE 104 U.S. MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER: SALES

AND FORECAST, THROUGH 2018 ($ MILLIONS) 160

TABLE 105 PATENT EXPIRIES ON CANCER CHEMOTHERAPY DRUGS 167

LIST OF FIGURES

SUMMARY FIGURE UTERINE/ENDOMETRIAL CANCER: TREATMENT AND DIAGNOSTICS,

GLOBAL MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 9

FIGURE 1 GLOBAL UTERINE CANCER DIAGNOSTIC TESTS: MARKET AND FORECAST,

2012-2018 ($ MILLIONS) 99

FIGURE 2 GLOBAL MARKET FOR ENDOMETRIAL BIOPSY FOR UTERINE CANCER:

SALES AND FORECAST 2012-2018 ($ MILLIONS) 101

FIGURE 3 GLOBAL MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER:

SALES AND FORECAST, 2012-2018 ($ MILLIONS) 102

FIGURE 4 U.S. MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER: SALES

AND FORECAST, 2012-2018 ($ MILLIONS) 103

FIGURE 5 GLOBAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TEST MARKET AND

FORECAST, 2012-2018 ($ MILLIONS) 106

FIGURE 6 GLOBAL MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND

FORECAST, 2012-2018 ($ MILLIONS) 112

FIGURE 7 U.S. MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND FORECAST,

2012-2018 ($ MILLIONS) 113

FIGURE 8 GLOBAL COMPUTED TOMOGRAPHY IMAGING MARKET FOR UTERINE

CANCER: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 116

FIGURE 9 U.S. COMPUTED TOMOGRAPHY IMAGING MARKET FOR CANCER: SALES

AND FORECAST, 2012-2018 ($ MILLIONS) 117

FIGURE 10 GLOBAL DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST,

2012-2018 ($ MILLIONS) 119

FIGURE 11 U.S. DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST,

2012-2018 ($ MILLIONS) 120

FIGURE 12 GLOBAL ENDOMETRIAL CANCER MARKET: SALES AND FORECAST BY

APPLICATION TYPE, 2012-2018 ($ MILLIONS) 126

FIGURE 13 GLOBAL MARKET FOR RADIATION USED TO TREAT UTERINE CANCER:

SALES AND FORECAST, 2012-2018 ($ MILLIONS) 129

FIGURE 14 U.S. MARKET FOR RADIATION USED TO TREAT UTERINE CANCER MARKET:

SALES AND FORECAST, 2012-2018 ($ MILLIONS) 131

FIGURE 15 GLOBAL CYTOTOXIC THERAPY MARKET, 2010 AND 2017 ($ MILLIONS) 134

FIGURE 16 U.S. CYTOTOXIC THERAPY MARKET, 2012-2018 ($ MILLIONS) 135

FIGURE 17 EUROPEAN CYTOTOXIC THERAPY MARKET, 2012-2018 ($ MILLIONS) 136

FIGURE 18 JAPANESE CYTOTOXIC THERAPY MARKET, 2012-2018 ($ MILLIONS) 137

FIGURE 19 GLOBAL MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER:

SALES AND FORECAST, 2012-2018 ($ MILLIONS) 159

FIGURE 20 U.S. MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER: SALES

AND FORECAST, 2011-2018 160

To order this report: Therapies and Diagnostics for Uterine Cancer http://www.reportlinker.com/p01658941/Therapies-and-Diagnostics-for-Uterine-Cancer.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: [email protected]: (339)-368-6001Intl: +1 339-368-6001

SOURCE Reportlinker